Impact of the Addition of Metformin to Abiraterone in Pre-docetaxel Metastatic Castration-resistant Prostate Cancer Patients Progressing on Abiraterone Treatment (MetAb-Pro): a Phase II Pilot Study

Trial Profile

Impact of the Addition of Metformin to Abiraterone in Pre-docetaxel Metastatic Castration-resistant Prostate Cancer Patients Progressing on Abiraterone Treatment (MetAb-Pro): a Phase II Pilot Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Abiraterone (Primary) ; Metformin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms METAB-PRO
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Sep 2014 ClinicalTrials.gov record states the change of patient population from "post-docetaxel" to "pre-docetaxel" metastatic castration-resistant prostate cancer patients, it is reflected in the official title also.
    • 09 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top